FDA cites Persōn & Covey for CGMP failures at its Glendale, CA drug plant and for selling unapproved Xerac AC and Drysol.
What happened
FDA inspected the Glendale, CA drug manufacturing facility from January 27 to February 6, 2025. Investigators found that the quality unit set aside four failing active-ingredient results on a bulk Xerac AC lot and released it on a single passing retest, that lab computers used shared passwords with no audit-trail review, and that a Solbar Zinc Sunscreen batch was pulled back from destruction and reworked without an approved protocol or batch record. The letter also says three OTC products failed pH or coal tar content tests in long-term stability studies without thorough investigation, that the products were reformulated without process validation, and that Xerac AC and Drysol are sold without FDA-approved applications.
What FDA found
The quality unit ignored four failing tests of the active ingredient in a bulk Xerac AC lot and released it after one passing retest.
21 CFR 211.22Lab software allowed shared passwords and a generic "System Administrator" account, and no one reviewed audit trails or electronic raw data.
21 CFR 211.22A Solbar Zinc Sunscreen batch approved for destruction was instead reworked and released without an approved protocol, a batch record, or quality assurance sign-off.
21 CFR 211.22Out-of-specification (results that fail a set specification) stability failures for three OTC products were closed at the first phase without a full investigation into manufacturing causes, and those products remain on the market within expiry.
21 CFR 211.192Three OTC products were reformulated between 2013 and 2018 without process validation or stability data to support their expiry dates; prior validation dated to 1999 and 2002.
21 CFR 211.100(a)Xerac AC and Drysol are promoted as antiperspirants for excessive sweating but have no FDA-approved application, making them unapproved new drugs.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
What FDA wants
FDA tells the company to reply in writing within 15 working days describing what it has done and how it will prevent recurrence, or to explain the delay and give a completion schedule. The letter also says to engage a qualified CGMP consultant and to supply full investigations, risk assessments, corrective action plans, and stability and validation programs.
Who should pay attention
- brands and retailers that buy OTC sunscreens and shampoos from this contract manufacturer
- distributors and sellers of Xerac AC and Drysol antiperspirants
- quality teams at small OTC makers running stability and out-of-specification investigations
This is a summary. Read the original letter on fda.gov.